India’s First Homegrown Antibiotic Zaynich Gets US FDA Approval

India has achieved a major milestone with the development of Zaynich, a breakthrough antibiotic created by Mumbai-based pharmaceutical company Wockhardt. The drug recently received approval from the United States Food and Drug Administration (US FDA). This approval holds significance because the US FDA is considered one of the world’s strictest drug regulators. Getting the approval means that a medicine has passed rigorous tests for safety, effectiveness and quality. Zaynich is the first fully homegrown Indian antibiotic to receive this recognition, marking a historic achievement for the country.

With this approval, Zaynich, can now be marketed in the United States for treating complicated urinary tract infections (cUTIs), including kidney infections known as pyelonephritis. Dennis Deruelle, MD, FHM, Chief Medical Officer at Wockhardt, in a press release, said, “The threat of drug-resistant infections is an escalating crisis, leaving clinicians with fewer tools to treat patients facing these aggressive pathogens. The FDA approval of Zaynich is a monumental step forward in validating a new option for these underserved populations. This milestone underscores our commitment to addressing critical unmet needs and offers a profound sense of hope to the families we are working to serve.

Dr. Habil F. Khorakiwala, Founder and Chairman of Wockhardt Group, said, “This approval is a significant realization of our mission to provide patients with novel antibiotics that help to address one of the most urgent global health threats – antimicrobial resistance. Furthermore, Zaynich is the first New Chemical Entity fully developed and commercialised by an Indian pharmaceutical company to receive an FDA approval, representing a historic milestone not only for Wockhardt, but for the Indian pharmaceutical industry.”

Zaynich is a novel injectable antibiotic developed to treat serious bacterial infections, especially complicated urinary tract infections. It is a combination of two components; cefepime, a fourth-generation cephalosporin antibiotic, and zidebactam, a new molecule developed by Wockhardt. Together, they work to attack harmful bacteria that have become resistant to many existing medicines. Unlike older antibiotics, Zaynich has been specifically designed to combat multidrug-resistant bacteria. (courtesy NDTV).(UPDATED ON 1ST JULY 2026)